Maryland State Retirement & Pension System Has $912,000 Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Maryland State Retirement & Pension System decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.1% during the 4th quarter, Holdings Channel reports. The firm owned 12,657 shares of the medical equipment provider’s stock after selling 542 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Hologic were worth $912,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in HOLX. Benson Investment Management Company Inc. bought a new position in shares of Hologic during the 4th quarter worth approximately $4,832,000. Principal Financial Group Inc. boosted its stake in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after acquiring an additional 1,606 shares in the last quarter. Clean Yield Group grew its holdings in Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Hologic during the 3rd quarter worth about $2,350,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $61.47 on Monday. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $13.79 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a 50 day moving average of $66.06 and a 200 day moving average of $73.94.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of research analyst reports. Citigroup decreased their target price on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Jefferies Financial Group initiated coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Finally, Wolfe Research started coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.